MUSC Hollings Cancer Center researcher Haizhen (Jen) Wang, Ph.D., recently was awarded a three-year $225,000 Young Investigator grant from the Melanoma Research Alliance.
researcher Haizhen (Jen) Wang, Ph.D., recently was awarded a three-year $225,000 Young Investigator grant from the Melanoma Research Alliance.
MRA research awards support innovative ideas that offer the promise of rapidly improving outcomes for patients facing melanoma. Each award was selected during MRA’s grant review through a rigorous peer review process and was confirmed by the MRA Board of Directors. The alliance, the largest nonprofit funder of melanoma research, announced $8.1 million in funding for 34 new awards that support research at 27 institutions in seven countries.
MRA chief science officer Marc Hurlbert, Ph.D., said in the company’s press release that MRA grant awards support scientists who are pushing the envelope in order to address some of the biggest unanswered questions in melanoma. “These include researchers working on modulating the microbiome to improve patient outcomes and others exploring strategies to understand and overcome resistance to therapies
MUSC Hollings Cancer Center researcher Haizhen (Jen) Wang, Ph.D., recently was awarded a three-year $225,000 Young Investigator grant from the Melanoma Research Alliance. The grant will help Wang further her research on T-cells and the tumor microenvironment in melanoma patients.
The Latest: Italy s Sardinia to open up as infections fall globegazette.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globegazette.com Daily Mail and Mail on Sunday newspapers.
WASHINGTON A U.S. advisory panel has endorsed the new one-dose COVID-19 vaccine from Johnson & Johnson as a third option to bolster the national effort against the coronavirus pandemic.
Advisers to the Centers for Disease Control and Prevention voted overwhelmingly to recommend the vaccine for adults 18 years old and up. The ruling followed emergency clearance of the vaccine by U.S. regulators a day earlier.
Members of the group emphasized that all three vaccines now available in the U.S. are highly protective against the worst effects of the virus, including hospitalization and death.
J&J plans to ship several million vaccine doses to states in the coming week, delivering a total of 20 million shots by the end of March. Health officials are eager to have an easier-to-use vaccine against COVID-19, which has killed more than 511,000 Americans and continues to mutate in troubling ways.